Recently, clinical trials in HER2-positive breast cancer patients with Trastuzumab-based neoadjuvant chemotherapy have produced a tremendous amount of multi-omics data along with well documented therapeutic endpoints, which provided great opportunity to develop big-data based predictive models [7, 8, 12–15]. This evidence concerns the gene ERBB2 and breast carcinoma.